의약품 설계 기반 품질 고도화(QbD)를 위한 QbD 6시그마 체계 구축에 관한 연구
A Study on the Build of a QbD Six Sigma System to Promote Quality Improvement(QbD) Based on Drug Design
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose: This study proposes the application of Six Sigma management innovation method for more systematically enhanced execution of Quality by Design (QbD) activities. QbD requires a deeper understanding of the product and process at the design and development stage of the drug, and it is very important to ensure that no fault is fundamentally generated through thorough process control. Methods: Analyzing the background and specific procedures of quality improvement based on the drug design basis, and analyzing the key contents of each step, we have differentated and common points from the 6 Sigma methodology. We propose a new model of Six Sigma management innovation method suitable for pharmaceutical industry. Results: Regulatory agencies are demanding results from statistical analysis as a scientific basis in developing medicines to treat human life through quality improvement activities based on drug design. By utilizing the education system to improve the statistical analysis capacity in the Six Sigma activities and operating the 6 Sigma Belt system in conjunction, it helped systematically strengthen the execution power of quality improvement activities based on pharmaceutical design based on the members of the pharmaceutical industry. Conclusion: By using QbD Six Sigma, which combines quality enhancement based on pharmaceutical design basis and Six Sigma methodology suitable for pharmaceutical industry, it is possible to obtain satisfactory results both by pharmaceutical companies and regulators by using appropriate statistical analysis methods for preparing scientific evidence data required by regulatory.
Abstract
Purpose: This study proposes the application of Six Sigma management innovation method for more systematically enhanced execution of Quality by Design (QbD) activities. QbD requires a deeper understanding of the product and process at the design and development stage of the drug, and it is very important to ensure that no fault is fundamentally generated through thorough process control. Methods: Analyzing the background and specific procedures of quality improvement based on the drug design basis, and analyzing the key contents of each step, we have differentated and common points from the 6 Sigma methodology. We propose a new model of Six Sigma management innovation method suitable for pharmaceutical industry. Results: Regulatory agencies are demanding results from statistical analysis as a scientific basis in developing medicines to treat human life through quality improvement activities based on drug design. By utilizing the education system to improve the statistical analysis capacity in the Six Sigma activities and operating the 6 Sigma Belt system in conjunction, it helped systematically strengthen the execution power of quality improvement activities based on pharmaceutical design based on the members of the pharmaceutical industry. Conclusion: By using QbD Six Sigma, which combines quality enhancement based on pharmaceutical design basis and Six Sigma methodology suitable for pharmaceutical industry, it is possible to obtain satisfactory results both by pharmaceutical companies and regulators by using appropriate statistical analysis methods for preparing scientific evidence data required by regulatory.
참고문헌 (19)
- Amit S. Patil, "Quality by Design(QbD) : A new concept for development of quality pharmaceuticals", International Journal of Pharmaceutical Quality Assurance, 4(2), pp.13~19 (2013)
- Anurag S. Rathore, "Roadmap for implementation of quality by design(QbD)for biotechnology products", Trends in Biotechnology, 27(9), pp.546~553 (2009)
- 조성우, "위험 요인 평가를 위한 FMEA의 일반 RPN 모형과 활용에 관한 연구", 품질경영학회지, 50(1), pp.125~138 (2022), 한국품질경영학회[DOI]
- 최석봉, "경영진과 종업원 간 보상격차가 기업성과에 미치는 영향 : 승진가능성 및 기회, 경영진에 대한 만족도의 조절효과", 품질경영학회지, 49(3), pp.313~326 (2021), 한국품질경영학회[DOI]
- Gulin Amasya, "QbD guided early pharmaceutical development study : Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment", International Journal of Pharmaceutics, 563, pp.110~121 (2019)
- 김강희, "A Study on the Development of the Key Promoting Talent in the 4th Industrial Revolution - Utilizing Six Sigma MBB competency-", 품질경영학회지, 45(4), pp.677~696 (2017), 한국품질경영학회[DOI]
- 김강희, "현장에 적합한 샤이니-시그마 기법 제안", 품질경영학회지, 45(2), pp.227~246 (2017), 한국품질경영학회[DOI]
- Kim, K. H., "A Case Study on QbD-6 sigma Method to the Pharmaceutical Department of L Company", ICIC Express Letters, Part B: Applications, 11(5), pp.501~508 (2020)
- Lawrence, Y, "Six Sigma Quality and Consortia", Pharmaceutical Engineering, 38(6), pp.8~10 (2018)
- 이예경, "동물 및 임상 시험의 시계열 프로파일 데이터 비교를 위한 유사성 지수 개발", 품질경영학회지, 49(2), pp.145~159 (2021), 한국품질경영학회[DOI]
- Sara Cunha, "Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review", Nanomedicine: Nanotechnology, Biology and Medicine, 28, pp.102206~ (2020)
- Yim, H. S., "Field of pharmaceutical bio industry" (2018), NeHa
- "ICH Guideline Q8. Pharmaceutical Development", ~
- "ICH Guideline Q9. Quality Risk Management", ~
- "ICH Guideline Q10. Pharmaceutical Quality System", ~
- "ICH Guideline Q11. Development and Manufacture of Drug Substances", ~
- "ICH Guideline Q12. Lifecycle Management", ~
- "ICH Guideline Q13. Continuous Manufacturing of Drug Substances and Drug Products", ~
- "ICH Guideline Q14. Analytical Procedure Development", ~